International Journal of Radiation Oncology * Biology * Physics
Volume 61, Issue 1 , Pages 52-59 , January 2005

Dosimetry and cancer control after low-dose-rate prostate brachytherapy

  • W. Robert Lee, M.S., M.D.

      Affiliations

    • Radiation Oncology, Winston-Salem, NC, USA
    • Corresponding Author InformationReprint requests to: W. Robert Lee, M.S., M.D., Department of Radiation Oncology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC, USA 27157-1030. Tel: (336) 716-4630; Fax: (336) 716-7837
    • ,
  • Allan F. deGuzman, Ph.D.

      Affiliations

    • Radiation Oncology, Winston-Salem, NC, USA
    • ,
  • Kevin P. McMullen, M.D.

      Affiliations

    • Radiation Oncology, Winston-Salem, NC, USA
    • ,
  • David L. McCullough, M.D.

      Affiliations

    • Department of Urology, Wake Forest University School of Medicine, Winston-Salem, NC, USA

Received 23 February 2004 ,Revised 30 April 2004 ,Accepted 3 May 2004.

References 

  1. Lee WR, Moughan J, Owen JB, et al.  The 1999 patterns of care study of radiotherapy in localized prostate carcinoma (A comprehensive survey of prostate brachytherapy in the United States). Cancer. 2003;98:1987–1994
  2. Blasko JC, Grimm PD, Sylvester JE, et al.  Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 2000;46:839–850
  3. Brachman DG, Thomas T, Hilbe J, et al.  Failure-free survival following brachytherapy alone or external beam irradiation alone for T1–2 prostate tumors in 2222 patients (Results from a single practice). Int J Radiat Oncol Biol Phys. 2000;48:111–117
  4. Grimm PD, Blasko JC, Sylvester JE, et al.  10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:31–40
  5. Kollmeier MA, Stock RG, Stone N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up (Importance of patient selection and implant quality). Int J Radiat Oncol Biol Phys. 2003;57:645–653
  6. Merrick GS, Butler WM, Galbreath RW, et al.  Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1–T3 prostate cancer. Int J Radiat Oncol Biol Phys. 2001;51:41–48
  7. Zelefsky MJ, Wallner KE, Ling CC, et al.  Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol. 1999;17:517–522
  8. Nag S, Bice W, DeWyngaert K, et al.  The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys. 2000;46:221–230
  9. Potters L, Huang D, Calugaru E, et al.  Importance of implant dosimetry for patients undergoing prostate brachytherapy. Urology. 2003;62:1073–1077
  10. Stock RG, Stone NN, Tabert A, et al.  A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 1998;41:101–108
  11. Stock RG, Stone NN. Importance of post-implant dosimetry in permanent prostate brachytherapy. Eur Urol. 2002;41:434–439
  12. Lee WR, deGuzman AF, Bare RL, et al.  Postimplant analysis of transperineal interstitial permanent prostate brachytherapy (Evidence for a learning curve in the first year at a single institution). Int J Radiat Oncol Biol Phys. 2000;46:83–88
  13. Blasko JC, Mate T, Sylvester JE, et al.  Brachytherapy for carcinoma of the prostate (Techniques, patient selection, and clinical outcomes). Semin Radiat Oncol. 2002;12:81–94
  14. Grimm PD, Blasko JC, Ragde H, et al.  Does brachytherapy have a role in the treatment of prostate cancer?. Hematol Oncol Clin North Am. 1996;10:653–673
  15. American Society for Therapeutic Radiology and Oncology Consensus Panel . Consensus statement (Guidelines for PSA following radiation therapy). Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
  16. Al Qaisieh B. Pre- and post-implant dosimetry (An inter-comparison between UK prostate brachytherapy centres). Radiother Oncol. 2003;66:181–183
  17. Dubois DF, Prestidge BR, Hotchkiss LA, et al.  Intraobserver and interobserver variability of MR imaging- and CT-derived prostate volumes after transperineal interstitial permanent prostate brachytherapy. Radiology. 1998;207:785–789
  18. Lee WR, Roach M, Michalski J, et al.  Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy. Int J Radiat Oncol Biol Phys. 2002;54:457–461
  19. Amdur RJ, Gladstone D, Leopold KA, et al.  Prostate seed implant quality assessment using MR and CT image fusion. Int J Radiat Oncol Biol Phys. 1999;43:67–72
  20. Chen ME, Johnston DA, Tang K, et al.  Detailed mapping of prostate carcinoma foci (Biopsy strategy implications). Cancer. 2000;89:1800–1809
  21. D'Amico AV, Tempany CM, Schultz D, et al.  Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate. Urology. 2003;62:1063–1067
  22. Vicini FA, Kestin LL, Martinez AA. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 1999;45:553–561

PII: S0360-3016(04)00781-3

doi: 10.1016/j.ijrobp.2004.05.006

International Journal of Radiation Oncology * Biology * Physics
Volume 61, Issue 1 , Pages 52-59 , January 2005

Article Tools

* Image Usage & Resolution